메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류
인문학
인문학 일반 역사학 철학 종교학 어문학 기타 인문학
사회과학
사회과학 일반 경영학 관광학 교육학 군사학 문헌정보학 법학 사회학 신문방송학 심리과학 정치외교학 지리학 행정학 경제학 무역학 인류학 기타 사회과학
자연과학
자연과학 일반 물리학 생물학 생활과학 수학·통계학 천문학 지구과학 화학 기타 자연과학
공학
공학 일반 건축공학 기계공학 산업공학 재료·에너지공학 전기전자공학 조선해양공학 화학공학 컴퓨터학 기타공학
의약학
의학 일반 간호학 수의학 약학 한의학 기초의학 임상의학 기타 의약학
농수해양학
농수해양학 일반 농학 수산학 식품과학 임학 축산학 해상운송학 기타 농수해양학
예술체육학
예술 일반 디자인 미술 미용 사진 음악학 의상 체육 공연매체예술 기타 예술체육학
복합학
학제간연구 과학기술학 뇌인지과학 기술정책 기타 복합학

ENG

추천
검색

논문 기본 정보

자료유형
학술저널
저자정보
저널정보
대한병리학회 Journal of Pathology and Translational Medicine Journal of Pathology and Translational Medicine 제51권 제2호
발행연도
2017.1
수록면
103 - 121 (19page)

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색

초록· 키워드

오류제보하기
With recent advances in molecular diagnostic methods and targeted cancer therapies, several molecular tests have been recommended for gastric cancer (GC) and colorectal cancer (CRC). Microsatellite instability analysis of gastrointestinal cancers is performed to screen for Lynch syndrome, predict favorable prognosis, and screen patients for immunotherapy. The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor has been approved in metastatic CRCs with wildtype RAS (KRAS and NRAS exon 2–4). A BRAF mutation is required for predicting poor prognosis. Additionally, amplification of human epidermal growth factor receptor 2 (HER2) and MET is also associated with resistance to EGFR inhibitor in metastatic CRC patients. The BRAF V600E mutation is found in sporadic microsatellite unstable CRCs, and thus is helpful for ruling out Lynch syndrome. In addition, the KRAS mutation is a prognostic biomarker and the PIK3CA mutation is a molecular biomarker predicting response to phosphoinositide 3-kinase/AKT/mammalian target of rapamycin inhibitors and response to aspirin therapy in CRC patients. Additionally, HER2 testing should be performed in all recurrent or metastatic GCs. If the results of HER2 immunohistochemistry are equivocal, HER2 silver or fluorescence in situ hybridization testing are essential for confirmative determination of HER2 status. Epstein-Barr virus–positive GCs have distinct characteristics, including heavy lymphoid stroma, hypermethylation phenotype, and high expression of immune modulators. Recent advances in next-generation sequencing technologies enable us to examine various genetic alterations using a single test. Pathologists play a crucial role in ensuring reliable molecular testing and they should also take an integral role between molecular laboratories and clinicians.
#Gastric neoplasms #Colorectal neoplasms #Molecular diagnosis #Prognosis #Targeted therapy

목차

등록된 정보가 없습니다.

참고문헌 (1)

참고문헌 신청
Bosman FT / 2010 / WHO classification of tumours of the digestive system / IARC Press : 13 ~ 177 | 2. [학술지(정기간행물)] - Jemal A / 2010 / Global patterns of cancer incidence and mortality rates and trends / Cancer Epidemiol Biomarkers Prev 19 : 1893 ~ 1907 | 3. [학술지(정기간행물)] - 오창모 / 2016 / Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2013 / Cancer Research and Treatment 48 (2) : 436 ~ 450 | 4. [학술지(정기간행물)] - 정규원 / 2016 / Prediction of Cancer Incidence and Mortality in Korea, 2016 / Cancer Research and Treatment 48 (2) : 451 ~ 457 | 5. [학술지(정기간행물)] - Boland CR / 1998 / A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition : development of international criteria for the determination of microsatellite instability in colorectal cancer / Cancer Res 58 : 5248 ~ 5257 | 6. [학술지(정기간행물)] - Douillard JY / 2013 / Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer / N Engl J Med 369 : 1023 ~ 1034 | 7. [학술지(정기간행물)] - Lee HS / 2004 / Epstein-barr virus-positive gastric carcinoma has a distinct protein expression profile in comparison with epstein-barr virus-negative carcinoma / Clin Cancer Res 10 : 1698 ~ 1705 | 8. [학술지(정기간행물)] - Bang YJ / 2010 / Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial / Lancet 376 : 687 ~ 697 | 9. [단행본] - Amin MB / 2017 / AJCC cancer staging manual / Spinger : 203 ~ 274 | 10. [학술지(정기간행물)] - Jun SY / 2016 / Clinicopathologic and prognostic associations of KRAS and BRAF mutations in small intestinal adenocarcinoma / Mod Pathol 29 : 402 ~ 415 | 11. [학술지(정기간행물)] - Peltomaki P / 2003 / Role of DNA mismatch repair defects in the pathogenesis of human cancer / J Clin Oncol 21 : 1174 ~ 1179 | 12. [학술지(정기간행물)] - Ionov Y / 1993 / Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis / Nature 363 : 558 ~ 561 | 13. [학술지(정기간행물)] - Boland CR / 2005 / Evolution of the nomenclature for the hereditary colorectal cancer syndromes / Fam Cancer 4 : 211 ~ 218 | 14. [학술지(정기간행물)] - Hampel H / 2010 / Point: justification for Lynch syndrome screening among all patients with newly diagnosed colorectal cancer / J Natl Compr Canc Netw 8 : 597 ~ 601 | 15. [학술지(정기간행물)] - Kloor M / 2011 / Analysis of EPCAM protein expression in diagnostics of Lynch syndrome / J Clin Oncol 29 : 223 ~ 227 | 16. [학술지(정기간행물)] - Huth C / 2012 / The molecular basis of EPCAM expression loss in Lynch syndrome-associated tumors / Mod Pathol 25 : 911 ~ 916 | 17. [학술지(정기간행물)] - Watson P / 2008 / The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome / Int J Cancer 123 : 444 ~ 449 | 18. [학술지(정기간행물)] - Kim JH / 2009 / Prognostic implications of CpG island hypermethylator phenotype in colorectal cancers / Virchows Arch 455 : 485 ~ 494 | 19. [학술지(정기간행물)] - Thibodeau SN / 1998 / Microsatellite instability in colorectal cancer: different mutator phenotypes and the principal involvement of hMLH1 / Cancer Res 58 : 1713 ~ 1718 | 20. [단행본] - Edge SB / 2010 / AJCC cancer staging manual / Springer : 241 ~ 249 | 21. [학술지(정기간행물)] - Sinicrope FA / 2006 / Prognostic impact of microsatellite instability and DNA ploidy in human colon carcinoma patients / Gastroenterology 131 : 729 ~ 737 | 22. [학술지(정기간행물)] - 김주연 / 2013 / Microsatellite Instability Status in Gastric Cancer: A Reappraisal of Its Clinical Significance and Relationship with Mucin Phenotypes / Journal of Pathology and Translational Medicine 47 (1) : 28 ~ 35 | 23. [학술지(정기간행물)] - Lee HS / 2002 / Distinct clinical features and outcomes of gastric cancers with microsatellite instability / Mod Pathol 15 : 632 ~ 640 | 24. [학술지(정기간행물)] - Choi YY / 2014 / Is microsatellite instability a prognostic marker in gastric cancer? A systematic review with meta-analysis / J Surg Oncol 110 : 129 ~ 135 | 25. [학술지(정기간행물)] - Cancer Genome Atlas Research Network / 2014 / Comprehensive molecular characterization of gastric adenocarcinoma / Nature 513 : 202 ~ 209 | 26. [학술지(정기간행물)] - Cancer Genome Atlas Research Network / 2012 / Comprehensive molecular characterization of human colon and rectal cancer / Nature 487 : 330 ~ 337 | 27. [학술지(정기간행물)] - Cristescu R / 2015 / Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes / Nat Med 21 : 449 ~ 456 | 28. [학술지(정기간행물)] - Sargent DJ / 2010 / Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer / J Clin Oncol 28 : 3219 ~ 3226 | 29. [학술지(정기간행물)] - Le DT / 2015 / PD-1 blockade in tumors with mismatch-repair deficiency / N Engl J Med 372 : 2509 ~ 2520 | 30. [학술지(정기간행물)] - Rosenbaum MW / 2016 / PD-L1 expression in colorectal cancer is associated with microsatellite instability, BRAF mutation, medullary morphology and cytotoxic tumor-infiltrating lymphocytes / Mod Pathol 29 : 1104 ~ 1112 | 31. [학술지(정기간행물)] - Xiao Y / 2015 / The microsatellite instable subset of colorectal cancer is a particularly good candidate for checkpoint blockade immunotherapy / Cancer Discov 5 : 16 ~ 18 | 32. [학술지(정기간행물)] - Boger C / 2016 / PD-L1 is an independent prognostic predictor in gastric cancer of Western patients / Oncotarget 7 : 24269 ~ 24283 | 33. [학술지(정기간행물)] - Moreira L / 2012 / Identification of Lynch syndrome among patients with colorectal cancer / JAMA 308 : 1555 ~ 1565 | 34. [학술지(정기간행물)] - Buhard O / 2004 / Quasimonomorphic mononucleotide repeats for high-level microsatellite instability analysis / Dis Markers 20 : 251 ~ 257 | 35. [학술지(정기간행물)] - Lindor NM / 2002 / Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors / J Clin Oncol 20 : 1043 ~ 1048 | 36. [학술지(정기간행물)] - de la Chapelle A / 2010 / Clinical relevance of microsatellite instability in colorectal cancer / J Clin Oncol 28 : 3380 ~ 3387 | 37. [학술지(정기간행물)] - Oh JR / 2012 / Microsatellite instability testing in Korean patients with colorectal cancer / Fam Cancer 11 : 459 ~ 466 | 38. [학술지(정기간행물)] - Lin EI / 2015 / Mutational profiling of colorectal cancers with microsatellite instability / Oncotarget 6 : 42334 ~ 42344 | 39. [학술지(정기간행물)] - Richman SD / 2009 / KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial / J Clin Oncol 27 : 5931 ~ 5937 | 40. [학술지(정기간행물)] - Phipps AI / 2013 / KRAS-mutation status in relation to colorectal cancer survival : the joint impact of correlated tumour markers / Br J Cancer 108 : 1757 ~ 1764 | 41. [학술지(정기간행물)] - Spano JP / 2005 / Epidermal growth factor receptor signaling in colorectal cancer: preclinical data and therapeutic perspectives / Ann Oncol 16 : 189 ~ 194 | 42. [학술지(정기간행물)] - Karapetis CS / 2008 / K-ras mutations and benefit from cetuximab in advanced colorectal cancer / N Engl J Med 359 : 1757 ~ 1765 | 43. [학술지(정기간행물)] - Van Cutsem E / 2009 / Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer / N Engl J Med 360 : 1408 ~ 1417 | 44. [학술지(정기간행물)] - Lievre A / 2008 / KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab / J Clin Oncol 26 : 374 ~ 379 | 45. [학술지(정기간행물)] - Smith G / 2010 / Activating K-Ras mutations outwith ‘hotspot’ codons in sporadic colorectal tumours : implications for personalised cancer medicine / Br J Cancer 102 : 693 ~ 703 | 46. [학술지(정기간행물)] - Vaughn CP / 2011 / Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer / Genes Chromosomes Cancer 50 : 307 ~ 312 | 47. [학술지(정기간행물)] - Heinemann V / 2014 / FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial / Lancet Oncol 15 : 1065 ~ 1075 | 48. [학술지(정기간행물)] - van Grieken NC / 2013 / KRAS and BRAF mutations are rare and related to DNA mismatch repair deficiency in gastric cancer from the East and the West: results from a large international multicentre study / Br J Cancer 108 : 1495 ~ 1501 | 49. [학술지(정기간행물)] - Lee SH / 2003 / BRAF and KRAS mutations in stomach cancer / Oncogene 22 : 6942 ~ 6945 | 50. [학술지(정기간행물)] - Bettington M / 2013 / The serrated pathway to colorectal carcinoma : current concepts and challenges / Histopathology 62 : 367 ~ 386 | 51. [학술지(정기간행물)] - Roth AD / 2010 / Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial / J Clin Oncol 28 : 466 ~ 474 | 52. [학술지(정기간행물)] - Sinicrope FA / 2015 / Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes / Gastroenterology 148 : 88 ~ 99 | 53. [학술지(정기간행물)] - Palomaki GE / 2009 / EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome / Genet Med 11 : 42 ~ 65 | 54. [학술지(정기간행물)] - De Roock W / 2010 / Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis / Lancet Oncol 11 : 753 ~ 762 | 55. [학술지(정기간행물)] - Di Nicolantonio F / 2008 / Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer / J Clin Oncol 26 : 5705 ~ 5712 | 56. [학술지(정기간행물)] - Kopetz S / 2015 / Phase II pilot study of vemurafenib in patients with metastatic BRAF-mutated colorectal cancer / J Clin Oncol 33 : 4032 ~ 4038 | 57. [학술지(정기간행물)] - Corcoran RB / 2015 / Combined BRAF and MEK inhibition with dabrafenib and trametinib in BRAF V600-mutant colorectal cancer / J Clin Oncol 33 : 4023 ~ 4031 | 58. [학술지(정기간행물)] - Hyman DM / 2015 / Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations / N Engl J Med 373 : 726 ~ 736 | 59. [학술지(정기간행물)] - Perrone F / 2009 / PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients / Ann Oncol 20 : 84 ~ 90 | 60. [학술지(정기간행물)] - Nam SK / 2016 / BRAF, PIK3CA, and HER2 oncogenic alterations according to KRAS mutation status in advanced colorectal cancers with distant metastasis / PLoS One 11 : e0151865 ~ | 61. [학술지(정기간행물)] - Prenen H / 2009 / PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer / Clin Cancer Res 15 : 3184 ~ 3188 | 62. [학술지(정기간행물)] - Janku F / 2013 / PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials / Cancer Res 73 : 276 ~ 284 | 63. [학술지(정기간행물)] - Mei ZB / 2016 / Prognostic role of tumor PIK3CA mutation in colorectal cancer: a systematic review and meta-analysis / Ann Oncol 27 : 1836 ~ 1848 | 64. [학술지(정기간행물)] - Liao X / 2012 / Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival / N Engl J Med 367 : 1596 ~ 1606 | 65. [학술지(정기간행물)] - Ogino S / 2014 / Discovery of colorectal cancer PIK3CA mutation as potential predictive biomarker : power and promise of molecular pathological epidemiology / Oncogene 33 : 2949 ~ 2955 | 66. [학술지(정기간행물)] - Franca LT / 2002 / A review of DNA sequencing techniques / Q Rev Biophys 35 : 169 ~ 200 | 67. [학술지(정기간행물)] - Ogino S / 2005 / Sensitive sequencing method for KRAS mutation detection by pyrosequencing / J Mol Diagn 7 : 413 ~ 421 | 68. [학술지(정기간행물)] - Ahmadian A / 2006 / Pyrosequencing: history, biochemistry and future / Clin Chim Acta 363 : 83 ~ 94 | 69. [학술지(정기간행물)] - Sundstrom M / 2010 / KRAS analysis in colorectal carcinoma: analytical aspects of pyrosequencing and allele-specific PCR in clinical practice / BMC Cancer 10 : 660 ~ | 70. [학술지(정기간행물)] - Altimari A / 2013 / 454 next generation-sequencing outperforms allele-specific PCR, Sanger sequencing, and pyrosequencing for routine KRAS mutation analysis of formalinfixed, paraffin-embedded samples / Onco Targets Ther 6 : 1057 ~ 1064 | 71. [학술지(정기간행물)] - Herreros-Villanueva M / 2014 / KRAS mutations: analytical considerations / Clin Chim Acta 431 : 211 ~ 220 | 72. [학술지(정기간행물)] - Kim MJ / 2012 / Different metastatic pattern according to the KRAS mutational status and site-specific discordance of KRAS status in patients with colorectal cancer / BMC Cancer 12 : 347 ~ | 73. [학술지(정기간행물)] - Miglio U / 2013 / Mutation analysis of KRAS in primary colorectal cancer and matched metastases by means of highly sensitivity molecular assay / Pathol Res Pract 209 : 233 ~ 236 | 74. [학술지(정기간행물)] - Gonzalez de Castro D / 2012 / A comparison of three methods for detecting KRAS mutations in formalin-fixed colorectal cancer specimens / Br J Cancer 107 : 345 ~ 351 | 75. [학술지(정기간행물)] - Oh JE / 2010 / Detection of low-level KRAS mutations using PNA-mediated asymmetric PCR clamping and melting curve analysis with unlabeled probes / J Mol Diagn 12 : 418 ~ 424 | 76. [학술지(정기간행물)] - Peeters M / 2013 / Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer / Clin Cancer Res 19 : 1902 ~ 1912 | 77. [학술지(정기간행물)] - Srinivasan M / 2002 / Effect of fixatives and tissue processing on the content and integrity of nucleic acids / Am J Pathol 161 : 1961 ~ 1971 | 78. [학술지(정기간행물)] - 이혜승 / 2014 / Effects of Fixation and Storage of Human Tissue Samples on Nucleic Acid Preservation / Journal of Pathology and Translational Medicine 48 (1) : 36 ~ 42 | 79. [학술지(정기간행물)] - Kamel-Reid S / 2012 / Validation of KRAS testing for anti-EGFR therapeutic decisions for patients with metastatic colorectal carcinoma / Arch Pathol Lab Med 136 : 26 ~ 32 | 80. [학술지(정기간행물)] - Yarden Y / 2001 / Untangling the ErbB signalling network / Nat Rev Mol Cell Biol 2 : 127 ~ 137 | 81. [학술지(정기간행물)] - Conradi LC / 2013 / Frequency of HER-2 positivity in rectal cancer and prognosis / Am J Surg Pathol 37 : 522 ~ 531 | 82. [학술지(정기간행물)] - Seo AN / 2014 / HER2 status in colorectal cancer: its clinical significance and the relationship between HER2 gene amplification and expression / PLoS One 9 : e98528 ~ | 83. [학술지(정기간행물)] - Sartore-Bianchi A / 2016 / Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial / Lancet Oncol 17 : 738 ~ 746 | 84. [학술지(정기간행물)] - Schmoll HJ / 2016 / Targeting HER2: precision oncology for colorectal cancer / Lancet Oncol 17 : 685 ~ 686 | 85. [학술지(정기간행물)] - Ramanathan RK / 2004 / Low overexpression of HER-2/neu in advanced colorectal cancer limits the usefulness of trastuzumab (Herceptin) and irinotecan as therapy: a phase II trial / Cancer Invest 22 : 858 ~ 865 | 86. [학술지(정기간행물)] - Hurwitz H / 2016 / Targeted therapy for gastrointestinaI (GI) tumors based on molecular profiles: early results from MyPathway, an open-label phase IIa basket study in patients with advanced solid tumors / J Clin Oncol 34 (Suppl) : 653 ~ | 87. [학술지(정기간행물)] - Bertotti A / 2011 / A molecularly annotated platform of patient-derived xenografts (“xenopatients”) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer / Cancer Discov 1 : 508 ~ 523 | 88. [학술지(정기간행물)] - Turner N / 2010 / Fibroblast growth factor signalling : from development to cancer / Nat Rev Cancer 10 : 116 ~ 129 | 89. [학술지(정기간행물)] - Dieci MV / 2013 / Fibroblast growth factor receptor inhibitors as a cancer treatment : from a biologic rationale to medical perspectives / Cancer Discov 3 : 264 ~ 279 | 90. [학술지(정기간행물)] - Bang YJ / 2015 / A randomized, open-label phase II study of AZD4547 (AZD) versus Paclitaxel (P) in previously treated patients with advanced gastric cancer (AGC) with fibroblast growth factor receptor 2 (FGFR2) polysomy or gene amplification (amp): SHINE study / J Clin Oncol 33 (Suppl) : 4014 ~ | 91. [학술지(정기간행물)] - Pearson A / 2016 / High-level clonal FGFR amplification and response to FGFR inhibition in a translational clinical trial / Cancer Discov 6 : 838 ~ 851 | 92. [학술지(정기간행물)] - Bardelli A / 2013 / Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer / Cancer Discov 3 : 658 ~ 673 | 93. [학술지(정기간행물)] - Lee J / 2015 / Gastrointestinal malignancies harbor actionable MET exon 14 deletions / Oncotarget 6 : 28211 ~ 28222 | 94. [학술지(정기간행물)] - Pietrantonio F / 2016 / MET-driven resistance to dual EGFR and BRAF blockade may be overcome by switching from EGFR to MET inhibition in BRAF-mutated colorectal cancer / Cancer Discov 6 : 963 ~ 971 | 95. [학술지(정기간행물)] - Davies KD / 2013 / Molecular pathways : ROS1 fusion proteins in cancer / Clin Cancer Res 19 : 4040 ~ 4045 | 96. [학술지(정기간행물)] - Shaw AT / 2014 / Crizotinib in ROS1-rearranged non-small-cell lung cancer / N Engl J Med 371 : 1963 ~ 1971 | 97. [학술지(정기간행물)] - Lee J / 2013 / Identification of ROS1 rearrangement in gastric adenocarcinoma / Cancer 119 : 1627 ~ 1635 | 98. [학술지(정기간행물)] - Amatu A / 2016 / NTRK gene fusions as novel targets of cancer therapy across multiple tumour types / ESMO Open 1 : e000023 ~ | 99. [학술지(정기간행물)] - Sartore-Bianchi A / 2016 / Sensitivity to entrectinib associated with a novel LMNA-NTRK1 gene fusion in metastatic colorectal cancer / J Natl Cancer Inst 108 : djv306 ~ | 100. [학술지(정기간행물)] - Kim KM / 2014 / Human epidermal growth factor receptor 2 testing in gastric cancer: recommendations of an Asia-Pacific task force. / Asia Pac J Clin Oncol 10 : 297 ~ 307 | 101. [학술지(정기간행물)] - Fox SB / 2012 / Gastric HER2 Testing Study (GaTHER): an evaluation of gastric/gastroesophageal junction cancer testing accuracy in Australia / Am J Surg Pathol 36 : 577 ~ 582 | 102. [학술지(정기간행물)] - Ruschoff J / 2012 / HER2 testing in gastric cancer: a practical approach / Mod Pathol 25 : 637 ~ 650 | 103. [학술지(정기간행물)] - Wolff AC / 2013 / Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update / J Clin Oncol 31 : 3997 ~ 4013 | 104. [학술지(정기간행물)] - Lee HE / 2013 / Clinical significance of intratumoral HER2 heterogeneity in gastric cancer / Eur J Cancer 49 : 1448 ~ 1457 | 105. [학술지(정기간행물)] - Koudelakova V / 2015 / Evaluation of HER2 gene status in breast cancer samples with indeterminate fluorescence in situ hybridization by quantitative real-time PCR / J Mol Diagn 17 : 446 ~ 455 | 106. [단행본] - Longnecker RM / 2013 / Fields virology / Lippincott-Williams and Wilkins : 1898 ~ 1959 | 107. [학술지(정기간행물)] - Ma C / 2016 / Programmed death-ligand 1 expression is common in gastric cancer associated with Epstein-Barr virus or microsatellite instability / Am J Surg Pathol 40 : 1496 ~ 1506 | 108. [학술지(정기간행물)] - Akihito Kawazoe / 2017 / Clinicopathological features of programmed death ligand 1 expression with tumor-infiltrating lymphocyte, mismatch repair, and Epstein–Barr virus status in a large cohort of gastric cancer patients / Gastric Cancer 20 (3) : 407 ~ 415 | 109. [학술지(정기간행물)] - Chetty R / 2012 / Gastrointestinal cancers accompanied by a dense lymphoid component: an overview with special reference to gastric and colonic medullary and lymphoepithelioma-like carcinomas / J Clin Pathol 65 : 1062 ~ 1065 | 110. [학술지(정기간행물)] - Gulley ML / 2001 / Molecular diagnosis of Epstein-Barr virus-related diseases / J Mol Diagn 3 : 1 ~ 10 | 111. [학술지(정기간행물)] - Ambinder RF / 1994 / Epstein-Barr-encoded RNA in situ hybridization: diagnostic applications / Hum Pathol 25 : 602 ~ 605 | 112. [학술지(정기간행물)] - Carethers JM / 2015 / Genetics and genetic biomarkers in sporadic colorectal cancer / Gastroenterology 149 : 1177 ~ 1190.e3 | 113. [학술지(정기간행물)] - Chia NY / 2016 / Molecular classification of gastric cancer / Ann Oncol 27 : 763 ~ 769 | 114. [학술지(정기간행물)] - Chevrier S / 2014 / Next-generation sequencing analysis of lung and colon carcinomas reveals a variety of genetic alterations / Int J Oncol 45 : 1167 ~ 1174 | 115. [학술지(정기간행물)] - Lin Y / 2015 / Gene mutations in gastric cancer: a review of recent next-generation sequencing studies / Tumour Biol 36 : 7385 ~ 7394 | 116. [학술지(정기간행물)] - Cerami E / 2012 / The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data / Cancer Discov 2 : 401 ~ 404 | 117. [학술지(정기간행물)] - Lee YS / 2014 / Genomic profile analysis of diffusetype gastric cancers / Genome Biol 15 : R55 ~ | 118. [학술지(정기간행물)] - Li X / 2016 / Distinct subtypes of gastric cancer defined by molecular characterization include novel mutational signatures with prognostic capability / Cancer Res 76 : 1724 ~ 1732 | 119. [학술지(정기간행물)] - D’Haene N / 2015 / Clinical validation of targeted next generation sequencing for colon and lung cancers / PLoS One 10 : e0138245 ~ | 120. [학술지(정기간행물)] - Mukherjee S / 2016 / Chromosomal microarray provides enhanced targetable gene aberration detection when paired with next generation sequencing panel in profiling lung and colorectal tumors / Cancer Genet 209 : 119 ~ 129 | 121. [학술지(정기간행물)] - Yu J / 2015 / Novel recurrently mutated genes and a prognostic mutation signature in colorectal cancer / Gut 64 : 636 ~ 645 | 122. [학술지(정기간행물)] - Marrone M / 2014 / Multi-marker solid tumor panels using next-generation sequencing to direct molecularly targeted therapies / PLoS Curr 6 | 123. [학술지(정기간행물)] - Wang K / 2011 / Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer / Nat Genet 43 : 1219 ~ 1223 | 124. [학술지(정기간행물)] - Wong SS / 2014 / Genomic landscape and genetic heterogeneity in gastric adenocarcinoma revealed by whole-genome sequencing / Nat Commun 5 : 5477 ~ | 125. [학술지(정기간행물)] - Ali SM / 2015 / Prospective comprehensive genomic profiling of advanced gastric carcinoma cases reveals frequent clinically relevant genomic alterations and new routes for targeted therapies / Oncologist 20 : 499 ~ 507 | 126. [학술지(정기간행물)] - Kuboki Y / 2016 / Comprehensive analyses using next-generation sequencing and immunohistochemistry enable precise treatment in advanced gastric cancer / Ann Oncol 27 : 127 ~ 133 | 127. [학술지(정기간행물)] - Bria E / 2016 / Comprehensive molecular portrait using next generation sequencing of resected intestinal-type gastric cancer patients dichotomized according to prognosis / Sci Rep 6 : 22982 ~ | 128. [학술지(정기간행물)] - Malapelle U / 2016 / Less frequently mutated genes in colorectal cancer: evidences from next-generation sequencing of 653 routine cases / J Clin Pathol 69 : 767 ~ 771 | 129. [학술지(정기간행물)] - Dallol A / 2016 / Clinical significance of frequent somatic mutations detected by high-throughput targeted sequencing in archived colorectal cancer samples / J Transl Med 14 : 118 ~ | 130. [학술지(정기간행물)] - Sakai K / 2015 / Extended RAS and BRAF mutation snalysis using next-generation sequencing / PLoS One 10 : e0121891 ~ | 131. [학술지(정기간행물)] - Magliacane G / 2015 / Rapid targeted somatic mutation analysis of solid tumors in routine clinical diagnostics / Oncotarget 6 : 30592 ~ 30603 google schola

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!

이 논문의 저자 정보

최근 본 자료

전체보기

댓글(0)

0